Skip to content
Screener

Insulet PODD Investing Cash Flow

Investing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
-$15.4B-739%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
-$87.34M-250%
Medtronic logo
MedtronicMDT
-$917M-87.1%
Beta Bionics logo
Beta BionicsBBNX
$26.93M
Embecta Corp. logo
Embecta Corp.EMBC
$9.5M+733%
Opko Health logo
Opko HealthOPK
$15.54M

Other financials

Income statement

See full
Revenue$801.7M+23.5%
Gross profit$562.6M+24.4%
Operating income$129.7M+7.1%
Net income$95.0M+322%
EPS (diluted)$1.37+328%

Balance sheet

See full
Cash & equivalents$534.9M-52.3%
Total debt$974.7M-47.6%
Total equity$1.4B-2.8%
Total assets$3.2B-8.8%

Cash flow

See full
Operating cash flow$88.4M-55.0%
CapEx$32.5M+74.7%
Free cash flow$55.9M-68.6%

Valuation

See full
Market cap$9.23B-52.7%
Enterprise value$9.67B-52.3%
P/E24.6×-58.1×
P/S-5.2×

Profitability

See full
Gross margin71.1%+0.3pp
Operating margin16.9%-0.4pp
Net margin12.3%+2.3pp
FCF margin9.6%-7.5pp

Returns & leverage

See full
Return on equity26%+6.8pp
Debt / equity0.7×-0.6×
Current ratio2.5×+0.2×

Where this comes from

Reported directly by Insulet in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.

The source filing: Insulet’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001145197-26-000169
(in millions)Six Months Ended / 2026Six Months Ended / 2025
Cash flows from investing activities
Capital expenditures(56.8)(30.9)
Investments in developed software(8.3)(8.0)
Net cash used in investing activities(65.1)(38.9)
Cash flows from financing activities
Proceeds from issuance of senior unsecured notes, net of issuance costs440.7
Repayment of convertible debt(541.5)
Settlement of capped call options75.7

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Insulet's investing cash flow?
Insulet (PODD) reported investing cash flow of -$37.4M in Q2 2026.
How has Insulet's investing cash flow changed year-over-year?
Insulet's investing cash flow decreased by 60.5% year-over-year, from -$23.3M to -$37.4M.
What is the long-term trend for Insulet's investing cash flow?
Over 4 years (2021 to 2025), Insulet's investing cash flow has grown at a 28.1% compound annual growth rate (CAGR), from -$82.7M to -$222.7M.
What does investing cash flow mean?
Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.

Ask your AI about Insulet's investing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude